methoxsalen capsule, liquid filled
strides pharma science limited - methoxsalen (unii: u4vj29l7bq) (methoxsalen - unii:u4vj29l7bq) - methoxsalen 10 mg - photochemotherapy (methoxsalen with long wave uva radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy. methoxsalen is intended to be administered only in conjunction with a schedule of controlled doses of long wave ultraviolet radiation. a. patients exhibiting idiosyncratic reactions to psoralen compounds. b. patients possessing a specific history of light sensitive disease states should not initiate methoxsalen therapy except under special circumstances. diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism. c. patients with melanoma or with a history of melanoma. d. patients with invasive squamous cell carcinomas. e. patients with aphakia, because of the significantly increased risk of retinal damage due to the abse
methoxsalen capsule, liquid filled
oceanside pharmaceuticals - methoxsalen (unii: u4vj29l7bq) (methoxsalen - unii:u4vj29l7bq) - methoxsalen 10 mg - photochemotherapy (methoxsalen with long-wave uva radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy. methoxsalen is intended to be administered only in conjunction with a schedule of controlled doses of long-wave ultraviolet radiation. a. patients exhibiting idiosyncratic reactions to psoralen compounds. b. patients possessing a specific history of light-sensitive disease states should not initiate methoxsalen therapy except under special circumstances. diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism. c. patients with melanoma or with a history of melanoma. d. patients with invasive squamous cell carcinomas. e. patients with aphakia because of the significantly increased risk of retinal damage due to the absence of lenses.
methoxsalen capsule, liquid filled
actavis pharma, inc. - methoxsalen (unii: u4vj29l7bq) (methoxsalen - unii:u4vj29l7bq) - methoxsalen 10 mg - photochemotherapy (methoxsalen with long wave uva radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy. methoxsalen capsules, usp (soft gelatin capsules) are intended to be administered only in conjunction with a schedule of controlled doses of long wave ultraviolet radiation. - patients exhibiting idiosyncratic reactions to psoralen compounds. - patients possessing a specific history of light sensitive disease states should not initiate methoxsalen therapy except under special circumstances. diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism. - patients with melanoma or with a history of melanoma. - patients with invasive squamous cell carcinomas. - patients with aphakia, because of the significantly increased risk of retinal damag
oxsoralen-ultra- methoxsalen capsule, liquid filled
bausch health us, llc - methoxsalen (unii: u4vj29l7bq) (methoxsalen - unii:u4vj29l7bq) - methoxsalen 10 mg - photochemotherapy (methoxsalen with long-wave uva radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy. methoxsalen is intended to be administered only in conjunction with a schedule of controlled doses of long-wave ultraviolet radiation. a. patients exhibiting idiosyncratic reactions to psoralen compounds. b. patients possessing a specific history of light-sensitive disease states should not initiate methoxsalen therapy except under special circumstances. diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism. c. patients with melanoma or with a history of melanoma. d. patients with invasive squamous cell carcinomas. e. patients with aphakia because of the significantly increased risk of retinal damage due to the absence of lenses.
uvadex- methoxsalen injection, solution
therakos, inc. - methoxsalen (unii: u4vj29l7bq) (methoxsalen - unii:u4vj29l7bq) - methoxsalen 20 ug in 1 ml - uvadex® (methoxsalen) sterile solution is indicated for extracorporeal administration with the therakos® cellex® photopheresis system in the palliative treatment of the skin manifestations of cutaneous t-cell lymphoma (ctcl) that is unresponsive to other forms of treatment. - uvadex® (methoxsalen) sterile solution is contraindicated in patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, other psoralen compounds or any of the excipients. patients possessing a specific history of a light sensitive disease state should not initiate methoxsalen therapy. diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum and albinism. - uvadex® sterile solution is contraindicated in patients with aphakia, because of the significantly increased risk of retinal damage due to the absence of lenses. - patients should not receive uvadex® if they have any contraindications to the photop
methoxsalen macopharma 20 µg/ml blood fraction modification sol. amp.
macopharma - methoxsalen 0,02 mg/ml - solution for blood fraction modification - 20 µg/ml - methoxsalen 0.02 mg - other immunostimulants
methoxsalen 10mg tablets
special order - methoxsalen - oral tablet - 10mg
methoxsalen 1.2% bath additive
special order - methoxsalen - bath additive - 12mg/1ml
methoxsalen 0.15% topical emulsion
special order - methoxsalen - cutaneous emulsion - 1.5mg/1ml
methoxsalen 0.005% gel
special order - methoxsalen - cutaneous gel - 50microgram/1gram